Rezatopopt sees a path forward after all
Pivotal data set the stage for slightly delayed US accelerated approval filing.
World Lung 2025 – Candel looks to a new agla-vec use
But results come from a curated dataset, with no in-trial comparator.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
World Lung 2025 – Bristol seeks PRMT5 biomarkers
A common mutation comes into play for PRMT5 inhibition.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
